The active tivantinib as a single agent showed strong inhibition of various tumor-promoting signaling molecules, such as reduced RalB, CD44, c-Myc, and Id1 as well as inhibition of Akt activation, whereas the inactive enantiomer did not elicit much effect (Figure 8). The gene discussed is RALB; the disease is neoplasm.